ATE447417T1 - Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie - Google Patents
Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapieInfo
- Publication number
- ATE447417T1 ATE447417T1 AT05722089T AT05722089T ATE447417T1 AT E447417 T1 ATE447417 T1 AT E447417T1 AT 05722089 T AT05722089 T AT 05722089T AT 05722089 T AT05722089 T AT 05722089T AT E447417 T1 ATE447417 T1 AT E447417T1
- Authority
- AT
- Austria
- Prior art keywords
- denotes
- analogas
- angiotensin
- conjugates
- peptide
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20040953 | 2004-03-04 | ||
| PCT/NO2005/000078 WO2005084715A2 (en) | 2004-03-04 | 2005-03-03 | Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE447417T1 true ATE447417T1 (de) | 2009-11-15 |
Family
ID=34918859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05722089T ATE447417T1 (de) | 2004-03-04 | 2005-03-03 | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7763234B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1729823B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007526300A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1925876A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE447417T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602005017475D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005084715A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
| WO2006036071A2 (en) * | 2004-09-29 | 2006-04-06 | Ge Healthcare As | Urokinase plasminogen activator receptor targeted contrast agent |
| AU2005307195A1 (en) * | 2004-11-22 | 2006-05-26 | Ge Healthcare As | Contrast agents to target extracellular matrix |
| WO2010089757A2 (en) * | 2008-11-07 | 2010-08-12 | Usv Limited | An improved process for synthesis of cyclic octapeptide |
| US9730916B2 (en) * | 2014-02-27 | 2017-08-15 | Chang Gung Memorial Hospital, Keelung | Nutritional composition and method for improving heart failure |
| EP3759121A1 (en) | 2018-03-01 | 2021-01-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966896A (en) | 1974-09-06 | 1976-06-29 | Mallinckrodt, Inc. | Radioimmunoassay for plasma renin activity |
| US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4687659A (en) | 1984-11-13 | 1987-08-18 | Salutar, Inc. | Diamide-DTPA-paramagnetic contrast agents for MR imaging |
| WO1993012819A1 (en) | 1992-01-03 | 1993-07-08 | Rhomed Incorporated | Protein- and peptide-metal ion pharmaceutical applications |
| ATE314097T1 (de) * | 1996-10-28 | 2006-01-15 | Amersham Health As | Kontrastmittel |
| CA2269985A1 (en) | 1996-10-28 | 1998-05-07 | Aslak Godal | Improvements in or relating to diagnostic/therapeutic agents |
| US6230777B1 (en) | 1999-02-04 | 2001-05-15 | Midmac Systems, Inc. | Filter forming and joining apparatus |
| JP5043271B2 (ja) | 2000-04-12 | 2012-10-10 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | ペプチドベースの化合物 |
| WO2002020610A2 (en) * | 2000-09-07 | 2002-03-14 | Biosynthema Inc. | Conformationally constrained labeled peptides for imaging and therapy |
| GB0116815D0 (en) * | 2001-07-10 | 2001-08-29 | Nycomed Amersham Plc | Improved chelator conjugates |
| CN1622830A (zh) * | 2001-07-10 | 2005-06-01 | 安盛药业有限公司 | 肽基化合物 |
| GB0206750D0 (en) | 2002-03-22 | 2002-05-01 | Amersham Plc | Radiofluorination methods |
| NO20030115D0 (no) | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
-
2005
- 2005-03-03 CN CNA2005800066559A patent/CN1925876A/zh active Pending
- 2005-03-03 JP JP2007501740A patent/JP2007526300A/ja active Pending
- 2005-03-03 EP EP05722089A patent/EP1729823B1/en not_active Expired - Lifetime
- 2005-03-03 AT AT05722089T patent/ATE447417T1/de not_active IP Right Cessation
- 2005-03-03 US US10/591,047 patent/US7763234B2/en not_active Expired - Fee Related
- 2005-03-03 DE DE602005017475T patent/DE602005017475D1/de not_active Expired - Lifetime
- 2005-03-03 WO PCT/NO2005/000078 patent/WO2005084715A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1925876A (zh) | 2007-03-07 |
| DE602005017475D1 (de) | 2009-12-17 |
| JP2007526300A (ja) | 2007-09-13 |
| WO2005084715A2 (en) | 2005-09-15 |
| WO2005084715A3 (en) | 2006-06-15 |
| US20070297979A1 (en) | 2007-12-27 |
| EP1729823A2 (en) | 2006-12-13 |
| US7763234B2 (en) | 2010-07-27 |
| EP1729823B1 (en) | 2009-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG149895A1 (en) | Contrast agents for myocardial perfusion imaging | |
| IL180896A0 (en) | Method of tumour imaging | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| ATE439868T1 (de) | Targetingmittel für molekulare bilderzeugung | |
| ATE335515T1 (de) | Morpholinobildgebung und therapie | |
| GB0326546D0 (en) | Inhibitor imaging agents | |
| TNSN07401A1 (fr) | Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations | |
| DK1272507T3 (da) | Integrinbindende peptidderivater | |
| BRPI0416628A (pt) | uso de compostos orgánicos | |
| EP2253333A3 (en) | Contrast Agents for Myocardial Perfusion Imaging | |
| EP1778351A4 (en) | VERIFICATION OF LESIONAL FEATURES WITH BEAM SHAPES | |
| TR199802139T2 (xx) | Sisaprid'in an�nda tahliye sa�layan, PH'dan ba��ms�z kat� dozaj �ekli. | |
| NO20072120L (no) | Enzyme Inhibitor Imaging Agents | |
| DE502004005226D1 (de) | Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern | |
| DE602005017475D1 (de) | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie | |
| ATE272074T1 (de) | An neuropeptide gebundenes rgd (arg-gly-asp) | |
| WO2005053752A3 (en) | Novel imaging agents comprising caspase-3 inhibitors | |
| EP2340845A3 (en) | Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions | |
| DK1353948T3 (da) | Oplöselige biologiske analoge til bata-amyloidpeptid | |
| ATE425770T1 (de) | Kontrastmittel | |
| ATE289612T1 (de) | Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern | |
| EA202192551A1 (ru) | Способы диагностики рака легких | |
| ATE277352T1 (de) | Einetenascin-c isoform als marker für neoplasmen | |
| MA27772A1 (fr) | Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons | |
| BR0007702A (pt) | Método e kit de diagnóstico para diagnose de endometriose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |